$16.30 Million in Sales Expected for argenx SE – (NASDAQ:ARGX) This Quarter

Wall Street brokerages expect that argenx SE – (NASDAQ:ARGX) will announce sales of $16.30 million for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for argenx’s earnings. The lowest sales estimate is $8.96 million and the highest is $25.99 million. The firm is scheduled to announce its next earnings results before the market opens on Thursday, August 1st.

On average, analysts expect that argenx will report full-year sales of $83.98 million for the current financial year, with estimates ranging from $59.98 million to $108.98 million. For the next fiscal year, analysts expect that the company will post sales of $67.69 million, with estimates ranging from $28.01 million to $128.80 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover argenx.

ARGX has been the topic of a number of recent analyst reports. ValuEngine lowered shares of argenx from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Morgan Stanley raised their price target on shares of argenx from $143.00 to $173.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Stifel Nicolaus reissued a “buy” rating and set a $154.00 price target on shares of argenx in a research report on Thursday, August 1st. Wedbush raised their price target on shares of argenx from $144.00 to $170.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, Piper Jaffray Companies raised their price target on shares of argenx from $161.00 to $182.00 and gave the company an “overweight” rating in a research report on Thursday, May 23rd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $155.27.

Shares of ARGX traded down $2.06 during trading hours on Friday, reaching $134.28. 80,779 shares of the stock traded hands, compared to its average volume of 129,096. The company has a current ratio of 9.37, a quick ratio of 14.29 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $141.17 and a 200 day simple moving average of $130.25. argenx has a 52 week low of $63.81 and a 52 week high of $150.92. The company has a market cap of $4.32 billion, a price-to-earnings ratio of -57.14 and a beta of 1.17.

Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP bought a new stake in argenx in the first quarter worth about $121,000. SG Americas Securities LLC bought a new stake in argenx in the first quarter worth about $134,000. Flinton Capital Management LLC bought a new stake in argenx in the second quarter worth about $156,000. First Trust Advisors LP bought a new stake in argenx in the second quarter worth about $212,000. Finally, Shilanski & Associates Inc. bought a new stake in argenx in the second quarter worth about $215,000. 68.65% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

See Also: Overbought

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.